Isosorbide Mononitrate

• Angina Prevention
• Coronary Artery Disease
• Chronic Stable Angina
• Nitrate Therapy

Isosorbide mononitrate is an organic nitrate vasodilator used to prevent recurrent episodes of angina pectoris in patients with coronary artery disease. As the active metabolite of isosorbide dinitrate, it offers more predictable absorption and elimination, and the extended-release formulation supports a once-daily regimen that fits well into chronic stable angina management. Unlike sublingual nitroglycerin, it is intended to prevent angina episodes rather than abort them once they begin.

Mechanism of Action

Like all organic nitrates, isosorbide mononitrate acts as a prodrug for nitric oxide. Inside vascular smooth muscle, the molecule undergoes enzymatic biotransformation that releases NO, which activates soluble guanylate cyclase. The resulting rise in cyclic GMP triggers a cascade involving protein kinase G that lowers intracellular calcium, leading to relaxation of vascular smooth muscle.

The predominant clinical effect is venodilation, which reduces preload by pooling blood in the venous capacitance vessels. Lower left ventricular end-diastolic volume translates into reduced wall tension and a meaningful drop in myocardial oxygen demand — the central problem in angina. At higher doses, the drug also dilates large coronary arteries and contributes to mild arterial vasodilation, which lowers afterload. Together these effects rebalance myocardial oxygen supply and demand and prevent the ischemic chest pain of stable angina.

A crucial feature of nitrate pharmacology is tolerance: continuous receptor exposure rapidly blunts the vasodilatory effect, sometimes within 24 hours, through mechanisms that include depletion of sulfhydryl groups, neurohormonal counter-regulation with sodium retention, and oxidative stress on the vasculature. Dosing schedules deliberately preserve a nitrate-free interval of 10 to 14 hours each day so that responsiveness is maintained. This is why neither immediate-release nor extended-release isosorbide mononitrate is dosed around the clock the way many other cardiovascular drugs are.

Clinical Use

Isosorbide mononitrate is used to prevent — not abort — angina episodes in stable patients. It complements rather than replaces other anti-anginal therapy. Beta-blockers such as metoprolol, atenolol, or carvedilol, and calcium channel blockers such as amlodipine or diltiazem, are typically first-line for angina because they also reduce mortality after myocardial infarction. Long-acting nitrates are added when symptoms persist on these agents, and they are particularly useful for patients with predominantly evening or nocturnal angina when the dose can be timed to cover the symptomatic period while leaving an overnight nitrate-free window.

Ranolazine is another second-line option that does not lower heart rate or blood pressure and can be combined with nitrates when blood pressure is borderline. For acute relief of an angina episode, sublingual nitroglycerin remains the standard, and patients on long-acting nitrates should always have a current prescription on hand and know how to use it — sublingual tablets lose potency over time and should be replaced periodically. Patients with concurrent heart failure due to coronary artery disease often benefit from the preload-reducing effect, and combination hydralazine-isosorbide regimens have a specific role in self-identified Black patients with HFrEF, though that uses isosorbide dinitrate rather than mononitrate. Patients with supraventricular tachycardia or other rhythm disturbances should have their rhythm management optimized in parallel, since tachycardia significantly aggravates ischemia.

The AHA's overview of angina is a helpful patient resource. Our early warning signs of heart attack article outlines what symptoms should prompt urgent evaluation rather than self-treatment with a nitrate.

How to Take It

For immediate-release tablets, the asymmetric twice-daily schedule (for example, 8 AM and 3 PM) preserves an overnight nitrate-free interval. Extended-release tablets are taken once daily in the morning and should be swallowed whole — never crushed, split, or chewed, since doing so destroys the controlled-release matrix and can produce an unsafe spike in plasma concentration. Bedtime dosing is avoided because the nitrate-free interval needs to fall during sleep, when sympathetic tone is low and preload reduction is least needed.

Headache is the most common early side effect and reflects cerebral vasodilation; it usually fades within the first one to two weeks as patients accommodate. Acetaminophen is generally a better choice than NSAIDs for these headaches, since NSAIDs can blunt the cardiovascular benefit of nitrates and increase blood pressure. Sit or lie down when first taking a dose to limit dizziness from orthostatic hypotension. Do not stop the medication abruptly in patients who have been taking it for a long time, since rebound coronary vasoconstriction is possible. Sublingual nitroglycerin should remain on hand for acute episodes.

A strict warning: PDE-5 inhibitors used for erectile dysfunction (sildenafil, tadalafil, vardenafil, avanafil) and pulmonary hypertension are absolutely contraindicated. Combining the two classes can cause life-threatening hypotension. Patients should be counseled not to use these drugs at all while on chronic nitrate therapy, including over-the-counter supplements that may contain hidden PDE-5-active compounds. The same applies to riociguat. The minimum recommended washout if a patient must use both is 24 hours after sildenafil or vardenafil, and at least 48 hours after tadalafil — but in stable angina patients on daily nitrates, this washout is impractical and the safer course is to choose between nitrate therapy and PDE-5 use. Patients should also avoid alpha-blockers used for prostate symptoms or hypertension at the same time of day as the first nitrate dose, since the additive vasodilation can produce orthostatic syncope; staggering the doses helps. Concurrent NSAIDs are not absolutely contraindicated but tend to blunt the antihypertensive and possibly the antianginal effects of nitrates.

Monitoring and Follow-Up

Monitor blood pressure, heart rate, and symptom frequency at follow-up visits. A baseline ECG and assessment of left ventricular function are reasonable in all anginal patients. Lipid panel and HbA1c help guide concurrent risk factor modification — both are reviewed in our understanding blood work overview. If angina worsens in frequency, severity, or duration, or if it begins occurring at rest, the patient may have unstable disease and needs prompt evaluation, often with stress testing or coronary angiography. Patients on nitrates should be reminded at every visit about the absolute contraindication with PDE-5 inhibitors. Those with cardiovascular risk factors deserve continuous attention to blood pressure, lipid management with a statin such as atorvastatin or rosuvastatin, antiplatelet therapy with aspirin or clopidogrel where indicated, and lifestyle modification.

Special Populations

Older adults are more susceptible to orthostatic hypotension and falls; start at the lower end of the dosing range. Patients with significant hepatic impairment may have higher bioavailability and warrant a cautious start. Pregnancy and pediatric data are limited, and the drug is rarely used in these groups. Patients with hypertrophic obstructive cardiomyopathy or severe aortic stenosis should avoid nitrates because preload reduction can worsen outflow obstruction and precipitate syncope. Patients with right-ventricular infarction also tolerate nitrates poorly because they depend heavily on preload to maintain cardiac output. The MedlinePlus isosorbide mononitrate page provides a clear patient handout.

When to Contact Your Doctor

Seek emergency care for chest pain that is more severe than usual, lasts more than a few minutes despite rest and sublingual nitroglycerin, or is accompanied by sweating, nausea, breathlessness, or radiation to the jaw or arm — these may signal acute coronary syndrome. Fainting, severe lightheadedness, or a heart rate that feels persistently fast or slow also warrant prompt evaluation. Bluish lips or fingertips with severe headache could indicate methemoglobinemia, a rare but serious nitrate complication. Sudden vision changes, severe weakness, or trouble speaking might point to a different vascular emergency such as stroke and need 911 evaluation.

For patients learning to live with chronic angina, lifestyle measures matter as much as medication: smoking cessation, weight management, regular moderate-intensity activity (after appropriate cardiac risk stratification), Mediterranean-style eating, blood pressure and lipid control, and good sleep hygiene all reduce angina frequency and improve overall outcomes. Many patients are surprised how much symptom relief comes from these foundational habits, particularly when combined with appropriately titrated cardiovascular medications. Cardiac rehabilitation programs combine supervised exercise with risk factor counseling and demonstrably reduce mortality and recurrent events in coronary artery disease — they are appropriate after MI, after revascularization, and for many stable angina patients, yet remain underused.

If you have questions about isosorbide mononitrate or your angina treatment plan, our team at Zimmer Medical Group can help — contact us or schedule a visit.